Metsera (NASDAQ:MTSR - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Saturday.
MTSR has been the subject of a number of other reports. Wells Fargo & Company initiated coverage on Metsera in a research report on Friday, June 20th. They set an "overweight" rating and a $65.00 price objective for the company. Bank of America lifted their price target on shares of Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a research report on Thursday, August 28th. Finally, Guggenheim upped their price objective on shares of Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a report on Tuesday, June 10th. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Metsera currently has an average rating of "Buy" and an average price target of $59.00.
View Our Latest Research Report on MTSR
Metsera Stock Performance
Shares of NASDAQ:MTSR traded up $0.63 during trading on Friday, reaching $36.29. The stock had a trading volume of 1,107,739 shares, compared to its average volume of 1,249,355. The business has a fifty day moving average price of $34.58 and a 200-day moving average price of $28.65. Metsera has a 1-year low of $12.30 and a 1-year high of $47.40.
Metsera (NASDAQ:MTSR - Get Free Report) last posted its earnings results on Monday, July 28th. The company reported ($0.66) earnings per share for the quarter.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of MTSR. Alphabet Inc. acquired a new stake in Metsera during the 1st quarter worth $135,059,000. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Metsera in the first quarter valued at about $78,748,000. Wellington Management Group LLP acquired a new stake in shares of Metsera during the first quarter worth about $65,382,000. Alpha Wave Global LP purchased a new position in shares of Metsera during the first quarter worth about $64,894,000. Finally, Price T Rowe Associates Inc. MD acquired a new position in Metsera in the 1st quarter valued at about $42,395,000.
About Metsera
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Further Reading
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
